ARQ 197: Phase I/II started

ArQule began a double-blind, placebo-controlled Phase I/II trial to evaluate irinotecan and cetuximab with or without ARQ 197. ArQule is co-developing ARQ 197 with Daiichi on a worldwide basis outside...